Tay Hock, Wark Peter A B, Bartlett Nathan W
a Hunter Medical Research Institute , Newcastle , Australia.
b Priority Research Centre for Healthy Lungs , The University of Newcastle , Australia.
Expert Rev Respir Med. 2016 Jun;10(6):629-41. doi: 10.1080/17476348.2016.1180249. Epub 2016 May 3.
Viral exacerbations continue to represent the major burden in terms of morbidity, mortality and health care costs associated with asthma. Those at greatest risk for acute asthma are those with more severe airways disease and poor asthma control. It is this group with established asthma in whom acute exacerbations triggered by virus infections remain a serious cause of increased morbidity. A range of novel therapies are emerging to treat asthma and in particular target this group with poor disease control, and in most cases their efficacy is now being judged by their ability to reduce the frequency of acute exacerbations. Critical for the development of new treatment approaches is an improved understanding of virus-host interaction in the context of the asthmatic airway. This requires research into the virology of the disease in physiological models in conjunction with detailed phenotypic characterisation of asthma patients to identify targets amenable to therapeutic intervention.
就与哮喘相关的发病率、死亡率和医疗费用而言，病毒感染加重仍是主要负担。急性哮喘风险最高的人群是气道疾病更严重且哮喘控制不佳的患者。在这些已确诊哮喘的患者中，病毒感染引发的急性加重仍是发病率增加的一个严重原因。一系列新型疗法正在涌现以治疗哮喘，特别是针对疾病控制不佳的这一群体，而且在大多数情况下，现在通过它们减少急性加重频率的能力来评判其疗效。对新治疗方法的开发至关重要的是，在哮喘气道背景下更好地理解病毒与宿主的相互作用。这需要结合哮喘患者详细的表型特征，在生理模型中对该疾病的病毒学进行研究，以确定适合进行治疗干预的靶点。
